Illumina, Inc. (FRA:ILU)
79.44
+1.41 (1.81%)
At close: Sep 30, 2025
Illumina Employees
As of December 29, 2024, Illumina had 9,030 total employees, including 8,970 full-time and 60 part-time employees. The number of employees decreased by 1,610 or -15.13% compared to the previous year.
Employees
9,030
Change (1Y)
-1,610
Growth (1Y)
-15.13%
Revenue / Employee
€406,266
Profits / Employee
€119,206
Market Cap
12.45B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 9,030 | -1,610 | -15.13% |
Dec 31, 2023 | 10,640 | -920 | -7.96% |
Jan 1, 2023 | 11,560 | 1,710 | 17.36% |
Jan 2, 2022 | 9,850 | 2,000 | 25.48% |
Jan 3, 2021 | 7,850 | 150 | 1.95% |
Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Illumina News
- 4 days ago - ILMN Stock vs. IQV Stock - Forbes
- 7 days ago - Illumina advances personalized cancer care with new pharma development partnerships - PRNewsWire
- 12 days ago - Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - PRNewsWire
- 14 days ago - Bullish Two Hundred Day Moving Average Cross - ILMN - Nasdaq
- 15 days ago - CDC vaccine panel to meet this week: Here's what's at stake - CNBC
- 15 days ago - ILMN January 2028 Options Begin Trading - Nasdaq
- 19 days ago - Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says - South China Morning Post
- 27 days ago - Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - PRNewsWire